Moderna Receives Rare Sell Rating and 45% Decline Forecast After Cancer Vaccine News

Positive developments regarding Moderna's cancer vaccine have led to a rise in the company's stock, but this has also prompted a rare 'sell' recommendation from one analyst. The analyst suggests that the company's current valuation is overly optimistic and predicts that the stock could lose approximately 45% of its value in the coming period. This sell rating contrasts with the generally positive market sentiment, highlighting potential challenges the company may face. Notably, the commercial success of the cancer vaccine has yet to be proven, and its presence in a highly competitive market are among the analyst's concerns. Additionally, slowing sales momentum in the company's other products and high R&D expenditures could exert pressure on the valuation. In light of these developments, investors are advised to carefully assess the risks associated with Moderna's stock. This is not investment advice.

📊 MRNA — Piyasa Yorumu

▼ down · 65%

The headline includes a rare sell recommendation for Moderna, forecasting a sharp 45% decline, which could create negative pressure on the stock in the short term. Technical indicators present a mixed picture, with the price just below the 20- and 50-day moving averages, the RSI in neutral territory, and the MACD below its signal line. Despite a 5% rise over the last 24 hours, this negative news flow and analyst opinion may lead investors to take profits or adopt a cautious stance. In the short term, the likelihood of the price pulling back from current levels appears higher than an upward move.

RSI 14

47.5

MACD

1.46

24h Δ

5.09%

Canlı Grafikler